Drug/drug delivery systems for the prevention and treatment of vascular disease
First Claim
Patent Images
1. A drug delivery device comprising:
- an intraluminal medical device, the intraluminal medical device including a stent having a fenestrated structure, the stent comprising a plurality of bands and links defining a substantially tubular device with openings;
a polymeric coating affixed to the bands and links of the fenestrated structure, the polymeric coating including first and second layers; and
a therapeutic dosage of cell cycle inhibitors that act selectively at a G1 phase of a cell cycle incorporated into the polymeric coating for treatment of intimil hyperplasia, constrictive vascular remodeling, and inflammation caused by injury, the cell cycle inhibitors that act selectively at a G1 phase of a cell being incorporated into the first layer of the polymeric coating and the second layer acting as a diffusion layer, the total thickness of the polymeric coating is in the range from about one micron to about twenty microns with the first layer having a thickness in the range from about eight microns to about twelve microns and the second layer having a thickness in the range from about one micron to about two microns.
3 Assignments
0 Petitions
Accused Products
Abstract
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.
-
Citations
3 Claims
-
1. A drug delivery device comprising:
-
an intraluminal medical device, the intraluminal medical device including a stent having a fenestrated structure, the stent comprising a plurality of bands and links defining a substantially tubular device with openings;
a polymeric coating affixed to the bands and links of the fenestrated structure, the polymeric coating including first and second layers; and
a therapeutic dosage of cell cycle inhibitors that act selectively at a G1 phase of a cell cycle incorporated into the polymeric coating for treatment of intimil hyperplasia, constrictive vascular remodeling, and inflammation caused by injury, the cell cycle inhibitors that act selectively at a G1 phase of a cell being incorporated into the first layer of the polymeric coating and the second layer acting as a diffusion layer, the total thickness of the polymeric coating is in the range from about one micron to about twenty microns with the first layer having a thickness in the range from about eight microns to about twelve microns and the second layer having a thickness in the range from about one micron to about two microns. - View Dependent Claims (2, 3)
-
Specification